What Happens Now?
Once your doctor has prescribed VPRIV, we're here for you. We can arrange to have a Patient Access Manager meet with you prior to your infusion, to make sure your questions are answered as you get started on treatment. But before then, here's a rundown on what VPRIV is, and how it works.
Enzyme Replacement Therapy
Enzyme replacement therapies (ERTs) are administered by infusion, which means that they are injected directly into your bloodstream. VPRIV is indicated for long-term enzyme replacement therapy for patients with type 1 Gaucher disease.
How VPRIV works
VPRIV is designed to replace the deficient enzyme (glucocerebrosidase) that patients with type 1 Gaucher lack. It has the same amino acid sequence as the naturally produced enzyme that occurs in your body. In clinical trials, some patients experienced hypersensitivity, or a serious allergic reaction. The most commonly observed symptoms of hypersensitivity reactions were headache, dizziness, low or high blood pressure, nausea, tiredness/weakness, or fever. That’s why working with a medical professional is important.
How it may help*
At the end of a 12-month study, VPRIV improved several measures of type 1 Gaucher disease in 12 treatment-naïve patients who received 60 units per kilogram (U/kg) every other week.
increase in hemoglobin concentrations
- Mean hemoglobin concentration at start of trial: 10.6 g/dL
- Mean change from start of trial for patients receiving the 60 U/kg dose: 2.4 g/dL ± 0.3 [SE]
increase in platelet count
- Mean platelet count at start of trial: 97x109/L
- Mean change from start of trial for patients receiving the 60 U/kg dose: 51x109/L ± 12 [SE]
decrease in spleen size
- Mean spleen volume at start of trial: 2.9% of body weight
- Mean change from start of trial for patients receiving the 60 U/kg dose: -1.9% ± 0.5 of body weight [SE]
SE = Standard error
*Individual results may vary, so talk to your doctor about the risks and benefits of treatment options that may be right for you.
IMPORTANT SAFETY INFORMATION
VPRIV may not be right for everyone and should be given under the supervision of a healthcare professional with appropriate medical support available. There is a possibility of developing antibodies to VPRIV. It is unknown if having antibodies to VPRIV is related to a higher risk of infusion reactions. Patients with an immune response to other enzyme replacement therapies who are switching to VPRIV should continue to be watched for antibodies to VPRIV.
At first, VPRIV is taken at an infusion center, which is a site of care that focuses specifically on medications that are delivered intravenously. Your OnePath Patient Support Manager can help you find the one nearest to you.
Also, you may eventually be able to work with your doctor to arrange for your infusions to be taken at home.
“It took a while to get used to, but now infusions are just a part of my routine.”
living with type 1 Gaucher
For patients 4 years and older who are new to treatment, VPRIV is a 60-minute infusion taken once every other week under the supervision of a healthcare professional.
Though the infusion is scheduled for 60 minutes, you may need to stay longer for post-treatment monitoring.